Daiichi Sankyo (OTCMKTS:DSNKY) Sees Large Volume Increase – Should You Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw strong trading volume on Monday . 683,723 shares changed hands during mid-day trading, an increase of 161% from the previous session’s volume of 262,092 shares.The stock last traded at $21.31 and had previously closed at $21.84.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Daiichi Sankyo Stock Down 2.2%

The company’s 50-day simple moving average is $23.22 and its two-hundred day simple moving average is $23.85. The firm has a market cap of $40.44 billion and a PE ratio of 20.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.